PubMed Health⌕ Search

Biomedical subjects

V Yeragani

Publications and source records attributed to V Yeragani.

6 recordsLinked to original sources
PubMed1989

Lactate infusions in panic disorder patients and normal controls: autonomic measures and subjective anxiety.

The anxiety symptoms, heart rate and blood pressure of 61 patients who panicked during lactate infusions were compared with 25 control nonpanickers. There was no significant difference in the increase in heart rate and blood pressure over baseline between patients and controls. There appeared to be no significant correlation between the subjective anxiety ratings and the measures of heart rate and blood pressure during lactate-induced panic. The symptoms of shortness of breath, feeling frightened or afraid, feeling dizzy and fear of losing control were significantly associated with lactate-induced panic. In addition, the cognitive symptoms of fear of losing control and fear of going crazy appear to be important determinants of lactate-induced panic.

Adult↗
PubMed1987

Platelet serotonin levels in panic disorder.

Platelet serotonin levels were examined in 18 patients with panic disorder and compared to platelet serotonin levels of eight healthy controls. There was no statistically significant difference in the platelet serotonin levels between the two groups.

Adolescent↗
PubMed1987

A laboratory procedure for the induction of flashbacks.

The authors administered infusions of lactate intravenously to seven patients with a DSM-III diagnosis of posttraumatic stress disorder, six of whom also met DSM-III criteria for panic disorder. The lactate infusions resulted in flashbacks in all seven patients and panic attacks in six patients. The authors conclude that with further development intravenous lactate infusion may be used to study flashbacks and other dissociative phenomena and to determine the relationship between flashbacks and panic anxiety.

Anxiety Disorders↗
PubMed1987

Tiaspirone in schizophrenia.

It was predicted that tiaspirone, a novel compound, would benefit schizophrenic patients since in animal experiments it is a potent dopamine blocker. Following a placebo washout period of 1 to 2 weeks, 14 patients were treated for 28 days with the drug in a single-blind, dose ranging trial. GAS, NOSIE, and BPRS scores all showed significant improvement. No serious adverse effects were found. The absence of extrapyramidal symptoms was particularly encouraging since 10 of the 14 subjects had previously had them on other neuroleptics. Tiaspirone may represent a step forward in the search for a safer antipsychotic.

Adolescent↗